We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.
Neurology Diagnostics (NDx) is proud to have been selected for Lilly's ALZ 2 Trailblazer trial and has been seeing patients in this trial since July 2020. As part of the study, NDx has randomized 39 patients of the trial's >1700 patients
Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.
Neurology Diagnostics Newsletter Summary [date]
Accepting new patients, streamlined referrals, FDA-approved Alzheimer's drug Leqembi, and upcoming clinical trials for Alzheimer's, CTE, and Parkinson's. Join us in advancing neurological care.